Laser ablation with or without chemoembolization for unresectable neuroendocrine liver metastases: a pilot study. (May 2016)

• Record Type: Journal Article
• Authors: Pacella, Claudio Maurizio; Nasoni, Sara; Grimaldi, Franco; Di Stasio, Enrico; Misischi, Irene; Bianchetti, Sara; Papini, Enrico
• Is Part Of: International journal of endocrine oncology. Volume 3:Number 2(2016)
• Page Start: 97
• Page End: 107
• Publication Date: 2016-05
• Subjects: chemoembolization -- laser ablation -- liver metastastases -- neuroendocrine tumors; Endocrine glands -- Cancer -- Periodicals; 616.9944005
• DOI: 10.2217/ije.15.34
• Languages: English
• ISSNs: 2045-0869

Abstract

Aim: To evaluate the effectiveness of laser ablation (LA) with or without selective transarterial chemoembolization in patients with large, isolated or oligonodular unresectable neuroendocrine liver matastases.Materials & methods: Ten patients (mean age: 53.6 years ± 14.1; range: 24–79) with neuroendocrine tumors (NETs) and 13 liver matastases (mean diameter: 4.3 ± 2.8 cm; range: 1.5–12) underwent LA alone (n = 9) or LA followed by selective transarterial chemoembolization (n = 3).Results: Complete response was obtained in six patients with LA alone and in two patients with combined treatment. The 5-year overall survival rates from the initial diagnosis and post-treatment were 80 and 50%, respectively.Conclusion: This treatment modality may provide effective control of tumor burden and general symptoms improvement in patients with limited but unresectable disease.